The following is a summary of the REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript:

Financial Performance:

• The company's cash reserves increased from $314 million in Dec 2023 to $381 million in Mar 2024 due to proceeds from a public offering of common stock and pre-funded warrants.

• Q1 2024 research and development expenses stood at $55 million, down from $59 million in the same quarter of 2023 due to reduced manufacturing and clinical supply costs.

• The current cash runway is projected to fund operations into 2026.

Business Progress:

• Positive clinical outcomes were reported for RGX-202, a one-time gene therapy for Duchenne, with no serious adverse events.

• A new expansion phase of clinical development has begun after selecting the pivotal dose for RGX-202.

• The RGX-314 program for treating wet AMD and diabetic retinopathy is on track for enrollment with plans to file regulatory submissions by H1 2026.

• Plans are underway to file the company's first BLA using the accelerated approval pathway for the RGX-121 proposal by end of 2024.

• The company anticipates providing updates on the DMD program's strength and functional measures in H2.

• In collaboration with AbbVie, the company expects to advance the diabetic retinopathy treatment RGX-314 to pivotal phase by Q1 2025, with updates on wet AMD expected in Q3.

• Early clinical data suggest RGX-202 and RGX-314 may offer significant improvements compared to competing treatments, and the company is preparing for end-of-phase-2 discussions for RGX-314 in diabetic retinopathy.

More details: Regenxbio IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.